Completed PHASE3 INTERVENTIONAL 3-arm NCT00421109

Efficacy Study for the Symptomatic Treatment of Chronic Idiopathic Urticaria

Double-blind, Randomised, Placebo-controlled, Phase III Study Comparing the Efficacy and Safety of Bilastine 20 mg Once Daily and Levocetirizine 5 mg for the Treatment of Chronic Idiopathic Urticaria

Sponsor: Faes Farma, S.A.

Conditions Urticaria

Interventions Bilastine Levocetirizine Placebo

Updated 6 times since 2017 Last updated: Apr 4, 2012 Started: Jul 31, 2006 Primary completion: Jul 31, 2007 Completion: Jul 31, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00421109, this PHASE3 trial focuses on Urticaria and remains completed. Sponsored by Faes Farma, S.A., it has been updated 6 times since 2006, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Jul 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Faes Farma, S.A.

Data source: Faes Farma, S.A.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aalst, Belgium , Badalona, Spain , Barcelona, Spain , Berlin, Germany , Bilbao, Spain , Brasov, Romania , Bucharest, Romania , Buenos Aires, Argentina , Craiova Dolj, Romania , Edegem, Belgium and 25 more locations